News Articles

      • 10 November, 2014

    Q&A: Stem Cells, Regenerative Medicine, and Veterans

    Q&A with Dr. Anthony Atala, director of Wake Forest Institute for Regenerative Medicine, North Carolina, U.S.A., and leader of the consortium of researchers that make up the Armed Forces Institute of Regenerative Medicine (AFIRM). He spoke about the organization and its mission.
    Full story
      • 9 October, 2014

    From Stem Cells to Billions of Human Insulin Producing Cells

    With human embryonic stem cells as a starting point, the scientists are for the first time able to produce, in the kind of massive quantities needed for cell transplantation and pharmaceutical purposes, human insulin-producing beta cells equivalent in most every way to normally functioning beta cells.
    Full story
      • 14 August, 2014

    New CellNet Quality Control Tool Ensures Lab-created Cells Have the Right Properties

    Scientists at Boston Children’s Hospital, the Wyss Institute for Biologically Inspired Engineering at Harvard University and Boston University have created a computer algorithm called CellNet as a “roadmap” for cell and tissue engineering, to ensure that cells engineered in the lab have the same favorable properties as cells in our own bodies.
    Full story
      • 12 August, 2014

    The ISSCR Announces New Global Advisory Council Chairpersons

    Dr. Susan Lim and Mr. Deepak Sharma are appointed chairpersons of the ISSCR Global Advisory Council, which brings together academic, business, corporate, civic and philanthropic leaders interested in supporting the society in its mission to transform human health worldwide.
    Full story
      • 12 June, 2014

    Rudolf Jaenisch Assumes Leadership of the International Society for Stem Cell Research

    The International Society for Stem Cell Research (ISSCR) is pleased to announce Rudolf Jaenisch, Whitehead Institute for Biomedical Research and Massachusetts Institute of Technology (MIT), as incoming president of the ISSCR board of directors, immediately following the ISSCR’s 12th Annual Meeting, June 18-21, 2014. Jaenisch will serve as president for one year and succeeds Janet Rossant. The role of vice president will be filled by Sally Temple, Neural Stem Cell Institute.
    Full story
      • 9 May, 2014

    Stem Cells May be Key to Curing Retinal Disease

    Robin Ali, Ph.D., UCL Institute of Ophthalmology in London, has developed a strategy for repairing the retina by transplanting photoreceptor cells generated in the laboratory from embryonic stem cells.
    Full story
      • 7 April, 2014

    Organoids Offer Stem Cell Experts a Window into Kidney Disease

    Stem cell researchers are now using organoids, lab-grown models of human organs, to better understand kidney disease. In the future, organoids may also provide an important test model for experimental drugs.
    Full story
      • 10 March, 2014

    Details of ISSCR 12th Annual Meeting

    The ISSCR 12th Annual Meeting will take place June 18-21, 2014 at the Vancouver Convention Centre in Vancouver, British Columbia, Canada. The meeting will bring together approximately 4,000 stem cell scientists, bioethicists, clinicians and industry professionals from over 50 countries to present and discuss the latest research and technologies within the field.
    Full story
      • 6 March, 2014

    Human Disease Modeling Under the Microscope

    Induced pluripotent stem cells (iPS cells) have been hailed as a future cell therapy, but they are playing an equally important role in research, revolutionizing the way scientists study human disease. By cultivating human stem cell lines in a dish, scientists are better able to understand diseases, including those with unique genetic markers.
    Full story

    Two Papers Open a New Window into Pluripotency

    The ISSCR is pleased to help spread the news about two papers published online today in Nature that describe the induction of pluripotency in cells from a newborn mouse without the use of extrinsic transcription factors, chemical manipulation or nuclear transfer.
    Full story
      • 14 January, 2014

    The ISSCR Announces 2014 Awards Recipients

    The ISSCR announces recipients of its 2014 awards, which will be presented at the 12th Annual Meeting in Vancouver, taking place June 18-21, 2014.
    Full story
      • 7 November, 2013

    Workshop, "Stem Cell Therapies: Opportunities for Assuring the Quality and Safety of Unregulated Clinical Offerings"

    The ISSCR, the Institute of Medicine and the National Academy of Sciences, is hosting a Washington, DC-based workshop and live webcast examining the practice and consequences of unproven stem cell treatments on November 18, 2013 from 8:30 a.m.-5:30 p.m. EDT
    Full story
      • 12 September, 2013

    ISSCR Statement of Delivery of Unproven Autologous Cell-based Interventions to Patients

    The International Society for Stem Cell Research (ISSCR) urges medical licensing bodies, legal authorities, patient advocacy organizations, physicians, and others to exercise their influence to discourage commercial provision of unproven autologous cell-based interventions outside of clinical trials.
    Full story
      • 4 June, 2013

    ISSCR Celebrates Inaugural Issue of its Open Access Journal, Stem Cell Reports

    The International Society for Stem Cell Research (ISSCR) is excited to announce the inaugural issue of Stem Cell Reports, the society’s new open-access journal, published today. Stem Cell Reports, published for the ISSCR by Cell Press, presents high-quality, peer-reviewed research presenting conceptual or practical advances across the breadth of stem cell research and its applications to medicine, with a focus on shorter, single-point articles.
    Full story
      • 22 April, 2013

    ISSCR Emphasizes Importance of Regulatory Oversight for Stem Cell Products for Clinical Use

    The ISSCR urges Italian lawmakers to heed concerns of scientists around the world about the premature practice of unproven stem cell treatments and to recognize the importance of regulatory oversight and patient protection when developing new stem cell medicines.
    Full story